{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:52:20Z","timestamp":1783734740025,"version":"3.55.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:00:00Z","timestamp":1769385600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41584-025-01351-5","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T17:32:09Z","timestamp":1769448729000},"page":"272-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trials"],"prefix":"10.1038","volume":"22","author":[{"given":"Grace","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Cepica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Barbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilimbek","family":"Beketaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denesh","family":"Chitkara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4490-8427","authenticated-orcid":false,"given":"Anthony P.","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimon","family":"Korish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill A.","family":"Lindstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay P.","family":"Nikolov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoang","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7692-1768","authenticated-orcid":false,"given":"Christopher T.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3196-4371","authenticated-orcid":false,"given":"Teodora P.","family":"Staeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4092-7658","authenticated-orcid":false,"given":"Benjamin F.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Lupus Accelerating Breakthroughs Consortium CLASI Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,26]]},"reference":[{"key":"1351_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/j.1365-2133.2012.11106.x","volume":"168","author":"R Vasquez","year":"2013","unstructured":"Vasquez, R. et al. A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. Br. J. Dermatol. 168, 145\u2013153 (2013).","journal-title":"Br. J. Dermatol."},{"key":"1351_CR2","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/1346-8138.17161","volume":"51","author":"L Xie","year":"2024","unstructured":"Xie, L., Lopes Almeida Gomes, L., Stone, C. J., Faden, D. F. & Werth, V. P. An update on clinical trials for cutaneous lupus erythematosus. J. Dermatol. 51, 885\u2013894 (2024).","journal-title":"J. Dermatol."},{"key":"1351_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001114","volume":"11","author":"L Arnaud","year":"2024","unstructured":"Arnaud, L., Parodis, I., Devilliers, H. & Chasset, F. Clinical trial outcomes for SLE: what we have and what we need. Lupus Sci. Med. 11, e001114 (2024).","journal-title":"Lupus Sci. Med."},{"key":"1351_CR4","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1016\/j.jid.2024.07.032","volume":"144","author":"TB Cepica","year":"2024","unstructured":"Cepica, T. B., Gupta, R., Werth, V. P. & Chong, B. F. Severity scores for cutaneous lupus erythematosus. J. Invest. Dermatol. 144, 2354\u20132363 (2024).","journal-title":"J. Invest. Dermatol."},{"key":"1351_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.968469","volume":"9","author":"RG Gaffney","year":"2022","unstructured":"Gaffney, R. G., Werth, V. P. & Merola, J. F. Cutaneous lupus erythematosus disease assessment: highlighting CLE outcome measures. Front. Med. 9, 968469 (2022).","journal-title":"Front. Med."},{"key":"1351_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1093\/bjd\/ljad089","volume":"189","author":"LM Carter","year":"2023","unstructured":"Carter, L. M., Wigston, Z., Laws, P. & Vital, E. M. Rapid efficacy of anifrolumab across multiple subtypes of recalcitrant cutaneous lupus erythematosus parallels changes in discrete subsets of blood transcriptomic and cellular biomarkers. Br. J. Dermatol. 189, 210\u2013218 (2023).","journal-title":"Br. J. Dermatol."},{"key":"1351_CR7","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/art.39962","volume":"69","author":"R Furie","year":"2017","unstructured":"Furie, R. et al. Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 69, 376\u2013386 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"1351_CR8","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie, R. et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 63, 3918\u20133930 (2011).","journal-title":"Arthritis Rheum."},{"key":"1351_CR9","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1172\/JCI124466","volume":"129","author":"R Furie","year":"2019","unstructured":"Furie, R. et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J. Clin. Invest. 129, 1359\u20131371 (2019).","journal-title":"J. Clin. Invest."},{"key":"1351_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/acr.22971","volume":"69","author":"L Iaccarino","year":"2017","unstructured":"Iaccarino, L. et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res. 69, 115\u2013123 (2017).","journal-title":"Arthritis Care Res."},{"key":"1351_CR11","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","volume":"386","author":"JT Merrill","year":"2022","unstructured":"Merrill, J. T. et al. Phase 2 trial of iberdomide in systemic lupus erythematosus. N. Engl. J. Med. 386, 1034\u20131045 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1351_CR12","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.jaad.2018.06.040","volume":"79","author":"KJ Ker","year":"2018","unstructured":"Ker, K. J., Teske, N. M., Feng, R., Chong, B. F. & Werth, V. P. Natural history of disease activity and damage in patients with cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 79, 1053\u20131060 e1053 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1351_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaad.2024.11.036","volume":"92","author":"AM Bender","year":"2025","unstructured":"Bender, A. M., Laageide, L., Kaur, J., Babkowski, N. & Richardson, C. T. Ruxolitinib cream for discoid lupus erythematosus: An open-label pilot study of 10 subjects. J. Am. Acad. Dermatol. 92, 655\u2013657 (2025).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1351_CR14","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/j.0022-202X.2005.23889.x","volume":"125","author":"J Albrecht","year":"2005","unstructured":"Albrecht, J. et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J. Invest. Dermatol. 125, 889\u2013894 (2005).","journal-title":"J. Invest. Dermatol."},{"key":"1351_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.21037\/atm-20-5048","volume":"9","author":"S Chakka","year":"2021","unstructured":"Chakka, S. et al. The CLASI, a validated tool for the evaluation of skin disease in lupus erythematosus: a narrative review. Ann. Transl. Med. 9, 431 (2021).","journal-title":"Ann. Transl. Med."},{"key":"1351_CR16","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/art.23319","volume":"59","author":"MS Krathen","year":"2008","unstructured":"Krathen, M. S. et al. The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. Arthritis Rheum. 59, 338\u2013344 (2008).","journal-title":"Arthritis Rheum."},{"key":"1351_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1001\/archdermatol.2010.435","volume":"147","author":"R Klein","year":"2011","unstructured":"Klein, R. et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch. Dermatol. 147, 203\u2013208 (2011).","journal-title":"Arch. Dermatol."},{"key":"1351_CR18","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1111\/bjd.15902","volume":"178","author":"MP Arevalo-Bermudez","year":"2018","unstructured":"Arevalo-Bermudez, M. P., Pita-Fernandez, S., Paradela, S. & Fonseca, E. Cutaneous lupus erythematosus: quality of life and related factors in a cohort of 260 patients from A Coruna, Spain. Br. J. Dermatol. 178, e117\u2013e118 (2018).","journal-title":"Br. J. Dermatol."},{"key":"1351_CR19","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1016\/j.jaad.2020.07.047","volume":"84","author":"S Chakka","year":"2021","unstructured":"Chakka, S. et al. Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 84, 1562\u20131567 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1351_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1001\/2013.jamadermatol.467","volume":"149","author":"AY Chang","year":"2013","unstructured":"Chang, A. Y., Ghazi, E., Okawa, J. & Werth, V. P. Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus. JAMA Dermatol. 149, 104\u2013106 (2013).","journal-title":"JAMA Dermatol."},{"key":"1351_CR21","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/archderm.144.8.1061","volume":"144","author":"E Gaines","year":"2008","unstructured":"Gaines, E. et al. Quality of life and disease severity in a cutaneous lupus erythematosus pilot study. Arch. Dermatol. 144, 1061\u20131062 (2008).","journal-title":"Arch. Dermatol."},{"key":"1351_CR22","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1177\/0961203313509293","volume":"23","author":"M Ishiguro","year":"2014","unstructured":"Ishiguro, M., Hashizume, H., Ikeda, T., Yamamoto, Y. & Furukawa, F. Evaluation of the quality of life of lupus erythematosus patients with cutaneous lesions in Japan. Lupus 23, 93\u2013101 (2014).","journal-title":"Lupus"},{"key":"1351_CR23","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1093\/bjd\/ljae183","volume":"191","author":"MJ Mallbris","year":"2024","unstructured":"Mallbris, M. J., Jia, B., Zhao, Y., Kahlenberg, J. M. & Gudjonsson, J. E. Concomitant moderate to severe cutaneous lesions have marked impact on quality of life in patients with active systemic lupus erythematosus: a cross-sectional insight from two phase 3 randomised clinical trials in adults. Br. J. Dermatol. 191, 458\u2013460 (2024).","journal-title":"Br. J. Dermatol."},{"key":"1351_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-000444","volume":"8","author":"D Yan","year":"2021","unstructured":"Yan, D. et al. Cutaneous lupus concerns from the patient perspective: a qualitative study. Lupus Sci. Med. 8, e000444 (2021).","journal-title":"Lupus Sci. Med."},{"key":"1351_CR25","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41584-025-01247-4","volume":"21","author":"H Nguyen","year":"2025","unstructured":"Nguyen, H. & Staeva, T. P. Lupus ABC spearheading a new era of collaboration to advance lupus drug development. Nat. Rev. Rheumatol. 21, 253\u2013254 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1351_CR26","first-page":"927","volume":"69","author":"DP Symmons","year":"1988","unstructured":"Symmons, D. P. et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q. J. Med. 69, 927\u2013937 (1988).","journal-title":"Q. J. Med."},{"key":"1351_CR27","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/art.1780350606","volume":"35","author":"C Bombardier","year":"1992","unstructured":"Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D. & Chang, C. H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 35, 630\u2013640 (1992).","journal-title":"Arthritis Rheum."},{"key":"1351_CR28","first-page":"288","volume":"29","author":"DD Gladman","year":"2002","unstructured":"Gladman, D. D., Ibanez, D. & Urowitz, M. B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29, 288\u2013291 (2002).","journal-title":"J. Rheumatol."},{"key":"1351_CR29","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1056\/NEJMoa051135","volume":"353","author":"M Petri","year":"2005","unstructured":"Petri, M. et al. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med. 353, 2550\u20132558 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1351_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000529","volume":"8","author":"LN Guo","year":"2021","unstructured":"Guo, L. N. et al. Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need. Lupus Sci. Med. 8, e000529 (2021).","journal-title":"Lupus Sci. Med."},{"key":"1351_CR31","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1111\/j.1365-2133.2010.09799.x","volume":"163","author":"A Kuhn","year":"2010","unstructured":"Kuhn, A. et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br. J. Dermatol. 163, 898\u2013899 (2010).","journal-title":"Br. J. Dermatol."},{"key":"1351_CR32","first-page":"S227","volume":"33","author":"VP Werth","year":"2024","unstructured":"Werth, V. P. et al. Development of a conceptual model of the patient experience of disease activity in cutaneous lupus erythematosus. Qual. Life Res. 33, S227\u2013S227 (2024).","journal-title":"Qual. Life Res."},{"key":"1351_CR33","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1111\/bjd.17636","volume":"180","author":"ME Ogunsanya","year":"2019","unstructured":"Ogunsanya, M. E., Cho, S. K., Hudson, A. & Chong, B. F. Validation and reliability of a disease-specific quality-of-life measure in patients with cutaneous lupus erythematosus. Br. J. Dermatol. 180, 1430\u20131437 (2019).","journal-title":"Br. J. Dermatol."},{"key":"1351_CR34","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","volume":"19","author":"AY Finlay","year":"1994","unstructured":"Finlay, A. Y. & Khan, G. K. Dermatology life quality index (DLQI) \u2014 a simple practical measure for routine clinical use. Clin. Exp. Dermatol. 19, 210\u2013216 (1994).","journal-title":"Clin. Exp. Dermatol."},{"key":"1351_CR35","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jid.2018.12.004","volume":"139","author":"S Erickson","year":"2019","unstructured":"Erickson, S. & Kim, B. S. Research techniques made simple: itch measurement in clinical trials. J. Invest. Dermatol. 139, 264\u2013269.e1 (2019).","journal-title":"J. Invest. Dermatol."},{"key":"1351_CR36","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/bjd\/ljaf165","volume":"93","author":"G Lu","year":"2025","unstructured":"Lu, G. et al. Erythema and scale in cutaneous lupus erythematosus significantly impacts patient quality of life and disease course impression. Br. J. Dermatol. 93, 558\u2013560 (2025).","journal-title":"Br. J. Dermatol."},{"key":"1351_CR37","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.jaad.2024.11.056","volume":"92","author":"TB Cepica","year":"2024","unstructured":"Cepica, T. B. et al. Smoking status is a negative predictor of six-month cutaneous lupus activity trends: a prospective cohort study. J. Am. Acad. Dermatol. 92, 912\u2013914 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1351_CR38","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/annrheumdis-2022-eular.690","volume":"81","author":"V Werth","year":"2022","unstructured":"Werth, V. et al. Improvement of individual mucocutaneous manifestations in patients with systemic lupus erythematosus treated with anifrolumab. Ann. Rheum. Dis. 81, 436\u2013437 (2022).","journal-title":"Ann. Rheum. Dis."},{"key":"1351_CR39","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/art.42917","volume":"76","author":"V Werth","year":"2024","unstructured":"Werth, V., Merola, J. F., Li, Q. Y., Yang, W. H. & Barbey, C. Effect of litifilimab on cutaneous lupus erythematosus disease area and severity index-activity (CLASI-A) Subcomponents and Physician Global Assessment-Skin (PGA-Skin) in patients with cutaneous lupus erythematosus (CLE) in a phase 2 study. Arthritis Rheumatol. 76, 1387\u20131390 (2024).","journal-title":"Arthritis Rheumatol."},{"key":"1351_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3899\/jrheum.220089","volume":"50","author":"C Stull","year":"2023","unstructured":"Stull, C., Sprow, G. & Werth, V. P. Cutaneous involvement in systemic lupus erythematosus: a review for the rheumatologist. J. Rheumatol. 50, 27\u201335 (2023).","journal-title":"J. Rheumatol."},{"key":"1351_CR41","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/bjd.17012","volume":"180","author":"CJ Kushner","year":"2019","unstructured":"Kushner, C. J. et al. Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists. Br. J. Dermatol. 180, 165\u2013171 (2019).","journal-title":"Br. J. Dermatol."},{"key":"1351_CR42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamadermatol.2024.5190","volume":"161","author":"L Xie","year":"2025","unstructured":"Xie, L. et al. Subtype and racial erythema variation for cutaneous lupus trials. JAMA Dermatol. 161, 67\u201374 (2025).","journal-title":"JAMA Dermatol."},{"key":"1351_CR43","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jaad.2023.09.077","volume":"90","author":"J Kleitsch","year":"2024","unstructured":"Kleitsch, J. et al. Change in disease activity needed for meaningful change in cutaneous lupus by patient characteristic: a retrospective analysis of a longitudinal database. J. Am. Acad. Dermatol. 90, 406\u2013408 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"1351_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/09612033241311335","volume":"34","author":"G Lu","year":"2025","unstructured":"Lu, G., Brown, L. S. & Chong, B. F. Systemic lupus erythematosus is a risk factor for having multiple subtypes of cutaneous lupus erythematosus. Lupus 34, 181\u2013186 (2025).","journal-title":"Lupus"},{"key":"1351_CR45","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1468-3083.2010.03844.x","volume":"25","author":"D Bein","year":"2011","unstructured":"Bein, D. et al. Evaluation of disease activity and damage in different subtypes of cutaneous lupus erythematosus using the CLASI. J. Eur. Acad. Dermatol. Venereol. 25, 652\u2013659 (2011).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"1351_CR46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1001\/archdermatol.2008.592","volume":"145","author":"A Kreuter","year":"2009","unstructured":"Kreuter, A. et al. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking. Arch. Dermatol. 145, 244\u2013248 (2009).","journal-title":"Arch. Dermatol."},{"key":"1351_CR47","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa2118024","volume":"387","author":"VP Werth","year":"2022","unstructured":"Werth, V. P. et al. Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N. Engl. J. Med. 387, 321\u2013331 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1351_CR48","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1056\/NEJMoa2118025","volume":"387","author":"RA Furie","year":"2022","unstructured":"Furie, R. A. et al. Trial of Anti-BDCA2 antibody litifilimab for systemic lupus erythematosus. N. Engl. J. Med. 387, 894\u2013904 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1351_CR49","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/art.42391","volume":"75","author":"E Morand","year":"2023","unstructured":"Morand, E. et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase ii, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 75, 242\u2013252 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"1351_CR50","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/S0140-6736(18)32167-6","volume":"392","author":"RF van Vollenhoven","year":"2018","unstructured":"van Vollenhoven, R. F. et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet 392, 1330\u20131339 (2018).","journal-title":"Lancet"},{"key":"1351_CR51","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41584-023-00993-7","volume":"19","author":"K Connelly","year":"2023","unstructured":"Connelly, K. et al. Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce. Nat. Rev. Rheumatol. 19, 592\u2013602 (2023).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1351_CR52","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1002\/art.27601","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill, J. T. et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 62, 3077\u20133087 (2010).","journal-title":"Arthritis Rheum."},{"key":"1351_CR53","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04877691 (2025)."},{"key":"1351_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1136\/annrheumdis-2014-eular.4384","volume":"73","author":"C Gordon","year":"2014","unstructured":"Gordon, C. et al. Effects of atacicept on disease activity in patients with moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial. Ann. Rheum. Dis. 73, 77\u201377 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"1351_CR55","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01702740 (2012)."},{"key":"1351_CR56","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","volume":"60","author":"RA Furie","year":"2021","unstructured":"Furie, R. A. et al. Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. Rheumatology 60, 5397\u20135407 (2021).","journal-title":"Rheumatology"},{"key":"1351_CR57","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02656082 (2018)."},{"key":"1351_CR58","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02847598 (2023)."},{"key":"1351_CR59","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05162586 (2025)."},{"key":"1351_CR60","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01845740 (2021)."},{"key":"1351_CR61","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill, J. T. et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 62, 222\u2013233 (2010).","journal-title":"Arthritis Rheum."},{"key":"1351_CR62","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03288324 (2024)."},{"key":"1351_CR63","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01294774 (2017)."},{"key":"1351_CR64","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05531565 (2023)."},{"key":"1351_CR65","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001112","volume":"11","author":"SRP McDonnell","year":"2024","unstructured":"McDonnell, S. R. P. et al. Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease. Lupus Sci. Med. 11, e001112 (2024).","journal-title":"Lupus Sci. Med."},{"key":"1351_CR66","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06015737 (2025)."},{"key":"1351_CR67","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace, D. J., Furie, R. A. & Tanaka, Y. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392, 476\u2013476 (2018).","journal-title":"Lancet"},{"key":"1351_CR68","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04186871 (2024)."},{"key":"1351_CR69","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05591222 (2025)."},{"key":"1351_CR70","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05629208 (2025)."},{"key":"1351_CR71","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03134222 (2020)."},{"key":"1351_CR72","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-001113","volume":"11","author":"DJ Burge","year":"2024","unstructured":"Burge, D. J., Werth, V. P., Boackle, S. A. & Posada, J. Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132. Lupus Sci. Med. 11, e001113 (2024).","journal-title":"Lupus Sci. Med."},{"key":"1351_CR73","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04781816 (2025)."},{"key":"1351_CR74","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03817424 (2024)."},{"key":"1351_CR75","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT01352988 (2014)."},{"key":"1351_CR76","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02927457 (2021)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01351-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01351-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01351-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T01:02:37Z","timestamp":1774573357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-025-01351-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,26]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1351"],"URL":"https:\/\/doi.org\/10.1038\/s41584-025-01351-5","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,26]]},"assertion":[{"value":"19 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.F.C. is an investigator for Biogen Incorporated and EMD Serono; has consulted for Amgen Incorporated, AstraZeneca, Biogen Incorporated, Bristol Meyers Squibb, EMD Serono and Lupus Research Alliance; receives royalties from MAPI Research Trust; served as a chairperson for a seminar sponsored by Amgen Incorporated; and was a speaker for Cesas Medical. V.P.W. has received grants from Amgen, Argenx, AstraZeneca, Biogen, BMS, Celgene, Corbus Pharmaceuticals, CSL Behring, Genentech, Gilead, Horizon, Janssen, Pfizer, Q32 Bio, Regeneron, Syntimmune, Ventus and Viela; and has consulted for AbbVie, Akari, Amgen, Argenx, AstraZeneca, Bayer, Beacon Bioscience, Biogen, BMS, Calyx, Cabaletta Bio, Celgene, Corcept, Crisalis, CSL Behring, Cugene, EMD Sorona, Genentech, Gilead, GSK, Incyte, Horizon, Janssen, Kezar, Kwoya Kirin, Lilly, Medscape, Merck, Nektar, Octapharma, Pfizer, Principia, Regeneron, Rome Pharmaceuticals, Sanofi, UCB, Viela Bio; and receives royalties from MAPI Research Trust. A.P.F. has received research support and is an investigator for Alexion, AstraZeneca, Castle Biosciences, Mallinckrodt, Pfizer and Priovant; he is a consultant for AbbVie, Biogen and Mallinckrodt; and is a speaker for AbbVie, Amgen, BMS and Mallinckrodt. C.B. is a former employee of Biogen and may hold stock in Biogen. The University of Pennsylvania owns the copyright for the CLASI. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}